Obermatt
See Similar Stocks →

Invivyd

NMQ:IVVD · US00534A1025
BiotechnologySmall

360

40
Profit price50
Owner Earnings Yield1
Dividend Yield1
Price/Sales85
EV / Gross Profit78
Price/Book56
Return on Capital43
Cash Return on Capital60
Return on Equity39
EBIT Margin19
Gross Profitability73
Accruals41
Owner Earnings Margin49
Sales growth67
Profit growth27
Reinvestment91
Price momentum28
Debt load56
Refinancing39
Debt Payback1
Liquidity49
Analyst ratings100
Expectations trend50
Market mood16
Value Creation10/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Invivyd clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQGM
Founded2020
Employees149
Websiteinvivyd.com
ISINUS00534A1025
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
Infectious DiseasesImmunologyBiotechnologyPharmaceuticalTherapeutics

Description

Invivyd, Inc., a biopharmaceutical company, focuses on the discovery, development and commercialization of monoclonal antibody (‘mAb’) therapies for the prevention and treatment of serious viral infectious diseases. The company is devoted to deliver…

Analysis

Middle-of-the-road

Invivyd, Inc. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

Valuation data is not available for this company.

The trajectory is moderate and the balance sheet is stretched. The company scores 10/20 on our value-creation score: creating some value. Analysts lean positive.

What to watch: Some accounting patterns deserve a closer look. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
40
2026

All-time high

56

Mar 2026

All-time low

40

Jun 2026

Average rank

48

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
85
—
—
—
Price/Earnings
28
—
—
—
Price/Book
56
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
44
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Invivyd with its peers
Vera Therapeutics
NMQ:VERA
44
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Seres Therapeutics
NSQ:MCRB
6
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Achieve Life Sciences
NAQ:ACHV
63
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
BridgeBio Oncology Therapeutics
NMQ:BBOT
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
BIOAGE Labs
NSQ:BIOA
23
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Acrivon Therapeutics
NMQ:ACRV
6
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →